Search results

Skip to results

Type

Type

Status (1 selected)

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1 to 15 of 32 results for hepatitis b chronic

  1. Hepatitis B (chronic): diagnosis and management (CG165)

    This guideline covers assessing and managing chronic hepatitis B in children, young people and adults. It aims to improve care for people with hepatitis B by specifying which tests and treatments to use for people of different ages and with different disease severities.

  2. Hepatitis B (QS65)

    This quality standard covers testing, diagnosing and managing hepatitis B in adults, young people and children (from birth). It describes high-quality care in priority areas for improvement.

  3. Tenofovir disoproxil for the treatment of chronic hepatitis B (TA173)

    Evidence-based recommendations on tenofovir disoproxil for treating chronic hepatitis B.

  4. Telbivudine for the treatment of chronic hepatitis B (TA154)

    Evidence-based recommendations on telbivudine (Sebivo) for treating chronic hepatitis B in adults.

  5. Liver disease (QS152)

    This quality standard covers identifying, assessing and managing chronic liver disease in children, young people and adults, and cirrhosis in young people and adults. It describes high-quality care in priority areas for improvement.

  6. Adefovir dipivoxil and peginterferon alfa-2a for the treatment of chronic hepatitis B (TA96)

    Evidence-based recommendations on adefovir dipivoxil (Hepsera) and peginterferon alfa-2a (Pegasys) for treating chronic hepatitis B in adults.

  7. Entecavir for the treatment of chronic hepatitis B (TA153)

    Evidence-based recommendations on entecavir for treating chronic hepatitis B in adults.

  8. Hepatitis B and C testing: people at risk of infection (PH43)

    This guideline covers raising awareness of and testing for hepatitis B and C infection. It aims to ensure that people at increased risk of hepatitis B and C infection are tested.

  9. Tuberculosis (NG33)

    This guideline covers preventing, identifying and managing latent and active tuberculosis (TB) in children, young people and adults. It aims to improve ways of finding people who have TB in the community and recommends that everyone under 65 with latent TB should be treated. It describes how TB services should be organised, including the role of the TB control board.

  10. Physical health of people in prison (NG57)

    This guideline covers assessing, diagnosing and managing physical health problems of people in prison. It aims to improve health and wellbeing in the prison population by promoting more coordinated care and more effective approaches to prescribing, dispensing and supervising medicines.

  11. Drug use disorders in adults (QS23)

    This quality standard covers assessment and treatment of drug use disorders in adults (aged 18 and over). It includes treating the misuse of opioids, cannabis, stimulants and other drugs in all settings, including inpatient and specialist residential and community-based treatment settings, and prison services. It describes high-quality care in priority areas for improvement.

  12. Cirrhosis in over 16s: assessment and management (NG50)

    This guideline covers assessing and managing suspected or confirmed cirrhosis in people who are 16 years or older. It aims to improve how cirrhosis is identified and diagnosed, and gives advice on the monitoring, prevention and early management of complications.

  13. Drug misuse in over 16s: psychosocial interventions (CG51)

    This guideline covers using psychosocial interventions to treat adults and young people over 16 who have a problem with or are dependent on opioids, stimulants or cannabis. It aims to reduce illicit drug use and improve people’s physical and mental health, relationships and employment.

  14. Tenofovir alafenamide for treating chronic hepatitis B (terminated appraisal) (TA435)

    NICE was unable to make a recommendation about the use in the NHS of tenofovir alafenamide for treating chronic hepatitis B because no evidence submission was received from Gilead, but will review this decision if the company decides to make a submission.

    Sections for TA435

  15. Rituximab for the treatment of relapsed or refractory chronic lymphocytic leukaemia (TA193)

    Evidence-based recommendations on rituximab for treating relapsed or refractory chronic lymphocytic leukaemia in adults.